Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford(Centre for Cancer Biology), Timothy P. Hughes(South Australia Pathology), Nancy Briggs(The University of Adelaide), Haley Altamura(South Australia Pathology), David M. Ross(South Australia Pathology), John Reynolds(Deakin University), Jodi Prime(South Australia Pathology), Bronte A. Jamison(South Australia Pathology), Alexandra L. Yeoman(South Australia Pathology), Stuart Phillis(South Australia Pathology), Jasmina Georgievski(South Australia Pathology), Mark Hertzberg(The University of Sydney), Brad Sullivan(South Australia Pathology), David T Yeung(South Australia Pathology), John F. Seymour(The Royal Melbourne Hospital), Chani Field(South Australia Pathology)
Cited by 177
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k